Synlife

Synlife is an early-stage biotechnology company developing a novel therapeutic platform based on engineered Synthetic Cells. Its lead program, SOBER, targets the rapid removal of ethanol from the blood for alcohol poisoning, while a second program aims to locally activate chemotherapeutics within solid tumors. The company is privately held, pre-revenue, and backed by venture capital and government grants, positioning itself at the intersection of advanced drug delivery and synthetic biology.

Bottom-up engineering of Synthetic Cells: liposome-based vesicles containing complex systems of enzymes and macromolecules designed to mimic cellular functions like metabolism for therapeutic applications.

In alcohol poisoning, Synlife's SOBER would compete against supportive care standards, representing a first-in-class mechanism. In oncology, the prodrug activation approach competes with other targeted delivery technologies (e.g., antibody-drug conjugates, nanoparticles) and prodrug strategies. The Synthetic Cell platform itself is a pioneering approach with few direct competitors.